NORGINE LAUNCHES MUGARD FOR ORAL MUCOSITIS IN SPAIN

Back to media releases
Next media release
14 September 2016

 

NORGINE LAUNCHES MUGARD® FOR ORAL MUCOSITIS IN SPAIN

 

London, Wednesday 14 September 2016, 07:00 BST. Norgine today announced that it has launched MUGARD®, a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy in Spain. Approximately 177,000 cases of oral mucositis occur each year in Spain.[1],[2]

 

MUGARD® is a mucoadhesive oral rinse proven to prevent and manage the lesions and symptoms of oral mucositis by adhering to the mucosal surface of the mouth and forming a soothing, protective layer.[3] Approximately 20-40% of patients receiving conventional chemotherapy and nearly all patients receiving head and neck radiation therapy suffer from oral mucositis[4]. With limited effective treatment options available, MUGARD® has been created for patients to take prior to and during cancer treatment to relieve the signs and symptoms of oral mucositis.

 

Peter Martin, Chief Operating Officer, Norgine said: “We are delighted to launch MUGARD® in Spain as it provides cancer patients with an important treatment for oral mucositis, when we know there are limited effective treatment options available. Managing the side effects of cancer treatment is essential to keeping patients on their cancer therapy.”

 

Norgine holds the rights to MUGARD® in Europe, Australia and New Zealand. Norgine anticipates further launches of MUGARD® in 2016 and 2017.

 

Ends

Notes to Editors:

About MUGARD®
MUGARD® Muco-Adhesive Oral Rinse is a non-sterile slightly viscous liquid, formulated to adhere to the mucosal surface of the mouth and thereby forms a soothing, protective layer.

About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.

For more information, visit www.abeonatherapeutics.com.

Media Contacts
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine

 

GL/MUG/0816/0007
September 2016
 

References

 

[1] Norgine data on file. MUGARD 5YP Forecast 2016, July 2016

[2] Norgine data on file. Epidemiology-SCP, June 2016

[3] Allison RR, Ambrad AA, Arshoun, et al. Cancer 2014; 120(9): 1433-1140

[4] Lalla RV, Saunders DP, Peterson DE. Dent Clin North Am 2014; 58(2): 341-9